IP Library Granted Patent US 8,540,968
Granted Patent B2
US 8,540,968 · App. 11/316,620 · Granted Sep 24, 2013

Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof

Inventors: Jamey Weichert (Fitchburg, WI); Marc Longino (Verona, WI); Anatoly Pinchuk (Madison, WI)
Assignee: Cellectar, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,540,968
App. No.
11/316,620
Granted
Sep 24, 2013
Kind
B2
Abstract

The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs.

Claims (7)

1. A method for detecting and locating a cancer in vivo, the method comprising the steps of:

administering 124 I-labeled 18-(p-Iodophenyl)octadecyl phosphocholine to the human subject; and

determining whether an organ suspected of having the cancer in the subject retains a higher level of 124 I-labeled 18-(p-Iodophenyl)octadecyl phosphocholine than surrounding region(s), wherein a higher retention region indicates detection and location of the cancer, wherein the detection is carried out by PET scanning.

2. The method of claim 1 , wherein the detection is carried out by a combination of PET scanning and CT or MRI scanning methods.

3. The method of claim 1 , wherein the cancer is selected from the group consisting of lung cancer, squamous cell carcinoma, melanoma, colorectal cancer, ovarian cancer, prostate cancer, glioma, breast cancer, carcinosarcoma, and pancreatic cancer.

4. The method of claim 1 , comprising administering between about 0.5 μCi and about 500 mCi of the 124 I-labeled 18-(p-Iodophenyl)octadecyl phosphocholine to the human subject.

5. The method of claim 1 , comprising administering less than 0.3 μg/kg of body weight of the 124 I-labeled 18-(p-Iodophenyl)octadecyl phosphocholine to the human subject.

Assignments (4)
MERGER Recorded Sep 30, 2011
From: CELLECTAR, INC.
To: CELL ACQUISITION CORP.
Reel/Frame 026995/0196 →
CHANGE OF NAME Recorded Sep 30, 2011
From: CELL ACQUISITION CORP.
To: CELLECTAR, INC.
Reel/Frame 026995/0295 →
CONVERSION Recorded Sep 26, 2011
From: CELLECTAR, LLC
To: CELLECTAR, INC.
Reel/Frame 026971/0246 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2006
From: WEICHERT, JAMEY; LONGINO, MARC; PINCHUK, ANATOLY
To: CELLECTAR, LLC
Reel/Frame 017753/0469 →
Continuity (4)
Continuation In Part 10906687 · Mar 2, 2005
Provisional Application 60593190 · Dec 20, 2004
Provisional Application 60521166 · Mar 2, 2004
Related Publication 20070020178A1 · Jan 25, 2007